转移性肾癌伴症状患者行减瘤性肾切除术:对肾细胞癌指南的启示
本研究为317例接受减瘤性肾切除术(CN)的转移性肾细胞癌(mRCC)患者的观察性研究,旨在明确症状性mRCC的比例、CN对症状改善及围手术期并发症的影响,并评估获益与危害的权衡。结果显示,2/3患者存在任何体征或症状,1/3存在局部症状;CN后任何症状缓解率和改善率分别为43%和71%,局部症状缓解率和改善率分别为91%和95%;任何并发症和重大并发症风险分别为37%和10%。
要点
- 2/3的mRCC患者存在任何体征或症状,1/3存在局部症状。
- CN后局部症状缓解率和改善率分别达91%和95%。
- 任何并发症和重大并发症风险分别为37%和10%。
核心结论
- CN对mRCC患者的症状状态有积极影响,且有益反应比例始终高于有害反应比例。
研究设计与样本
- 观察性研究,纳入317例接受减瘤性肾切除术的转移性肾细胞癌患者。
主要发现
- 局部、转移灶特异性和一般体征或症状的比例分别为37%、23%和27%。
- CN后任何体征或症状的缓解率和改善率分别为43%和71%。
- CN后局部体征或症状的缓解率和改善率分别为91%和95%。
- 任何并发症和重大并发症的风险分别为37%和10%。
- 回归分析显示症状状态与围手术期并发症无关。
关键数值与推荐
- 症状性mRCC定义为存在任何与疾病因果相关的体征或症状。
- 症状缓解定义为基线所有体征和症状均消失,改善定义为基线至少一种体征或症状消失。
- 围手术期并发症采用Clavien-Dindo分类评估。
- 根据症状改善与围手术期并发症的权衡,CN反应分为有益、混合或有害。
临床怎么用
- 多数mRCC患者存在症状,应知晓CN对症状状态有积极影响。
- CN可考虑用于改善mRCC患者的症状,但需权衡围手术期并发症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of cytoreductive nephrectomy (CN) patients with metastatic renal cell carcinoma (mRCC) is unclear. To define the proportion of symptomatic mRCC, to investigate the impact of CN on symptomatic improvement and perioperative morbidity, and to elucidate the trade-off between such benefit and harm, an observational study of 317 mRCC patients treated with CN was performed. Symptomatic mRCC was defined as the presence of any sign or symptom causally related to the disease. Sign or symptom resolution and improvement were defined as the absence of all the signs and symptoms recorded at baseline, and the absence of at least one sign or symptom recorded at baseline, respectively. Perioperative morbidity was assessed using the Clavien-Dindo classification. Response to CN was classified as beneficial, mixed, or harmful according to the trade-off between symptomatic improvement and perioperative morbidity. The proportions of local, metastasis-specific, and general signs or symptoms were 37%, 23%, and 27%, respectively. The proportions of any sign or symptom resolution and improvement after CN were 43% and 71%, respectively. The proportions of local sign or symptom resolution and improvement after CN were 91% and 95%, respectively. The risks of any complication and major complication were 37% and 10%, respectively. At regression analysis, symptomatic status was not associated with perioperative morbidity. The proportion of beneficial response was invariably higher than the proportion of harmful response. At mRCC diagnosis, two out of three patients suffer from any sign or symptom, and one out of three suffers from local signs or symptoms. CN has a positive impact on symptomatic status. PATIENT SUMMARY: Most metastatic renal cell carcinoma patients are symptomatic, and they should be aware that cytoreductive nephrectomy has a positive impact on symptomatic status.
引用
- Larcher A, Fallara G, Rosiello G, et al. Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. Eur Urol. 2020. PMID: 32507335. doi:10.1016/j.eururo.2020.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。